ASX - By Stock
|
ACW |
Re:
Ann: Trading Halt
|
|
revolution
|
20 |
3.8K |
5 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
20
|
3.8K
|
5
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW March 2024 quarterly activity report & Appendix 4C
|
|
revolution
|
12 |
2.2K |
0 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
12
|
2.2K
|
0
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW March 2024 quarterly activity report & Appendix 4C
|
|
revolution
|
12 |
2.2K |
1 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
12
|
2.2K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
Ann: First patient treated in ACW XanaMIA ph 2b Alzheimers trial
|
|
revolution
|
26 |
8.0K |
0 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
26
|
8.0K
|
0
|
|
ASX - By Stock
|
CHN |
Re:
Ann: Gonneville Resource Remodeled to Support Selective Mining
|
|
revolution
|
99 |
50K |
4 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
99
|
50K
|
4
|
|
ASX - By Stock
|
CHN |
Re:
Ann: Gonneville Resource Remodeled to Support Selective Mining
|
|
revolution
|
99 |
50K |
0 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
99
|
50K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Trading Halt
|
|
revolution
|
21 |
5.8K |
0 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
21
|
5.8K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Trading Halt
|
|
revolution
|
21 |
5.8K |
5 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
21
|
5.8K
|
5
|
|
ASX - By Stock
|
ACW |
Re:
Are Biotech stocks the next move?
|
|
revolution
|
28 |
9.8K |
2 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
28
|
9.8K
|
2
|
|
ASX - By Stock
|
CYP |
Re:
Ann: DFU Clinical Trial Enrolment Complete
|
|
revolution
|
22 |
5.4K |
2 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
22
|
5.4K
|
2
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW corporate presentation revised licensing slide
|
|
revolution
|
4 |
2.4K |
1 |
06/04/24 |
06/04/24 |
ASX - By Stock
|
4
|
2.4K
|
1
|
|
Charts
|
ACW |
Re:
ACW Chart Thread
|
|
revolution
|
24 |
8.5K |
0 |
04/04/24 |
04/04/24 |
Charts
|
24
|
8.5K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Neuren - where to from here ?
|
|
revolution
|
91 |
51K |
2 |
01/04/24 |
01/04/24 |
ASX - By Stock
|
91
|
51K
|
2
|
|
Charts
|
CHN |
Re:
CHN chart
|
|
revolution
|
7.6K |
3.2M |
0 |
31/03/24 |
31/03/24 |
Charts
|
7.6K
|
3.2M
|
0
|
|
Charts
|
CHN |
Re:
CHN chart
|
|
revolution
|
7.6K |
3.2M |
0 |
31/03/24 |
31/03/24 |
Charts
|
7.6K
|
3.2M
|
0
|
|
Charts
|
CHN |
Re:
CHN chart
|
|
revolution
|
7.6K |
3.2M |
0 |
31/03/24 |
31/03/24 |
Charts
|
7.6K
|
3.2M
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2023 Results webinar
|
|
revolution
|
130 |
62K |
6 |
30/03/24 |
30/03/24 |
ASX - By Stock
|
130
|
62K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
revolution
|
947 |
472K |
1 |
16/03/24 |
16/03/24 |
ASX - By Stock
|
947
|
472K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen announces $10 million rights offer
|
|
revolution
|
47 |
17K |
2 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
47
|
17K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
revolution
|
448 |
198K |
3 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
448
|
198K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
revolution
|
947 |
472K |
3 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
947
|
472K
|
3
|
|
Charts
|
ACW |
Re:
ACW Chart Thread
|
|
revolution
|
24 |
8.5K |
0 |
12/03/24 |
12/03/24 |
Charts
|
24
|
8.5K
|
0
|
|
Charts
|
ACW |
Re:
ACW Chart Thread
|
|
revolution
|
24 |
8.5K |
1 |
10/03/24 |
10/03/24 |
Charts
|
24
|
8.5K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
revolution
|
448 |
198K |
0 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
448
|
198K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
revolution
|
448 |
198K |
3 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
448
|
198K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
revolution
|
448 |
198K |
9 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
448
|
198K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
revolution
|
448 |
198K |
12 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
448
|
198K
|
12
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Encouraging Initial Data from CYP-006TK DFU Trial
|
|
revolution
|
49 |
9.9K |
6 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
49
|
9.9K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Comment on research report
|
|
revolution
|
316 |
160K |
5 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
316
|
160K
|
5
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Application for quotation of securities - ACW
|
|
revolution
|
25 |
6.5K |
0 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
25
|
6.5K
|
0
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Application for quotation of securities - ACW
|
|
revolution
|
25 |
6.5K |
4 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
25
|
6.5K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Comment on research report
|
|
revolution
|
316 |
160K |
8 |
18/02/24 |
18/02/24 |
ASX - By Stock
|
316
|
160K
|
8
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen awarded UK Innovation Passport for Xanamem
|
|
revolution
|
73 |
17K |
7 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
73
|
17K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Pause in Trading
|
|
revolution
|
45 |
24K |
6 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
45
|
24K
|
6
|
|
ASX - By Stock
|
ACW |
Re:
acw
|
|
revolution
|
26 |
8.5K |
2 |
10/02/24 |
10/02/24 |
ASX - By Stock
|
26
|
8.5K
|
2
|
|
ASX - By Stock
|
ACW |
Re:
ACW up +21% in last 6 months , up +54% YTD, good upside momentum into 2024 & 2025 results
|
|
revolution
|
8 |
3.3K |
0 |
07/02/24 |
07/02/24 |
ASX - By Stock
|
8
|
3.3K
|
0
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW December 2023 quarterly activity report & Appendix 4C
|
|
revolution
|
17 |
4.8K |
5 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
17
|
4.8K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
revolution
|
947 |
472K |
0 |
18/01/24 |
18/01/24 |
ASX - By Stock
|
947
|
472K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
News: ATX Amplia Therapeutics Says Approval From Korean Regulator
|
|
revolution
|
13 |
4.7K |
1 |
23/12/23 |
23/12/23 |
ASX - By Stock
|
13
|
4.7K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
News: ATX Amplia Therapeutics Says Approval From Korean Regulator
|
|
revolution
|
13 |
4.7K |
0 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
13
|
4.7K
|
0
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen receives $4.8 million R&D tax incentive rebate
|
|
revolution
|
10 |
4.1K |
3 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
10
|
4.1K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen receives $4.8 million R&D tax incentive rebate
|
|
revolution
|
10 |
4.1K |
3 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
10
|
4.1K
|
3
|
|
ASX - By Stock
|
ATX |
Re:
Ann: New Chief Financial Officer Mr Tim Luscombe
|
|
revolution
|
2 |
992 |
2 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
2
|
992
|
2
|
|
ASX - By Stock
|
NPM |
Re:
Ann: Amended 30 June 2022 NPM Cash Flow report
|
|
revolution
|
14 |
5.4K |
1 |
14/09/22 |
14/09/22 |
ASX - By Stock
|
14
|
5.4K
|
1
|
|
ASX - By Stock
|
ATX Biotech |
Re:
Valuation- Amplia is a sleeping giant
|
|
revolution
|
46 |
21K |
2 |
30/05/22 |
30/05/22 |
ASX - By Stock
|
46
|
21K
|
2
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Amplia Awarded $2.1M R&D Cash Flow Loan
|
|
revolution
|
6 |
1.7K |
2 |
06/12/21 |
06/12/21 |
ASX - By Stock
|
6
|
1.7K
|
2
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Amplia Provides Updated Investor Presentation
|
|
revolution
|
30 |
8.5K |
0 |
05/11/21 |
05/11/21 |
ASX - By Stock
|
30
|
8.5K
|
0
|
|
ASX - By Stock
|
NPM |
Re:
Ann: Las Tapias Lithium Project Update
|
|
revolution
|
105 |
43K |
2 |
16/08/18 |
16/08/18 |
ASX - By Stock
|
105
|
43K
|
2
|
|
ASX - By Stock
|
DCN |
Re:
Ann: Equity Raising Investor Presentation
|
|
revolution
|
67 |
33K |
2 |
25/07/18 |
25/07/18 |
ASX - By Stock
|
67
|
33K
|
2
|
|
ASX - By Stock
|
DCN |
Re:
A rare event
|
|
revolution
|
4 |
2.6K |
1 |
07/06/18 |
07/06/18 |
ASX - By Stock
|
4
|
2.6K
|
1
|
|